Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial

Lancet

Volumn 362, Issue 9377, 2003, Pages 14-21

  Cleland, J G F ^a,i   Pennell, D J ^b   Ray, S G ^c   Coats, A J ^b   Macfarlane, P W ^d   Murray, G D ^e   Dalle Mule, J ^f   Vered, Z ^g   Lahiri, A ^h  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f Ospedale Pieve di Cadore   (Italy)

^g ASSAF HAROFEH MEDICAL CENTER   (Israel)

^h NORTHWICK PARK HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PLACEBO;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL HIBERNATION; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

EID: 0037626650     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13801-9     Document Type: Article

References (26)

1. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
3. Study Group. M.E.R.I.T.-H.F. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007.
4. Cleland J.G.F., Bristow M., Erdmann E., Remme W.J., Swedberg K., Waagstein F. Beta-blocking agents in heart failure: should they be used and how? Eur Heart J. 17:1996;1629-1639.
5. Cleland J.G.F., Massie B.M., Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1:1999;41-45.
6. Doughty R.N., Whalley G.A., Gamble G., MacMahon S., Sharpe N. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 29:1997;1060-1066.
7. Bristow M.R. Why does the myocardium fail? Insights from basic science. Lancet. 352:(suppl I):1998;8-14.
8. Cleland J.G.F. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail. 4:2002;243-247.
9. O'Keefe J., Magalski A., Stevens T.L., et al. Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J Nucl Cardiol. 7:2000;3-7.
10. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
11. Woodley S.L., Gilbert E.M., Anderson J.L., et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:1991;2426-2441.
12. Packer M., Antonopoulos G.V., Berlin J.A., Chittams J., Konstam M.A., Udelson J.E. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 141:2001;899-907.
13. Unverferth D.V., Magorien R.D., Lewis R.P., Leier C.V. The role of subendocardial ischemia in perpetuating myocardial failure in patients with non-ischemic congestive cardiomyopathy. Am Heart J. 105:1983;176-179.
14. Medrano R., Lowry R.W., Young J.B., et al. Assessment of myocardial viability with (99m)Tc sestamibi in patients undergoing cardiac transplantation: a scintigraphic/pathological study. Circulation. 94:1996;1010-1017.
15. Fisher M.L., Gottlieb S.S., Plotnick G., et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 23:1994;943-950.
16. Cleland J.G.F., Pennell D.J., Ray S., et al. The Carvedilol Hibernation Reversible Ischaemia Trial: marker of success (CHRISTMAS). Eur J Heart Fail. 1:1999;191-196.
17. Pennell D.J., Ray S.G., Davies G., et al. The Carvedilol Hibernation Reversible Ischaemia Trial: Marker of Success (CHRISTMAS) study - methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. Int J Cardiol. 72:2000;265-274.
18. Kloner R.A., Bolli R., Marban E., Reinlib L., Braunwald E. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI Workshop. Circulation. 97:1998;1848-1867.
19. Canty J.M., Fallavollita J.A. Chronic hibernation and chronic stunning: a continuum. J Nucl Cardiol. 7:2000;509-527.
20. Kaprielian R.R., Gunning M., Dupont E., et al. Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation. 97:1998;651-660.
21. Schwartz E.R., Schoendube F.A., Kostis J., et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol. 31:1998;1018-1026.
22. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 39:2002;1151-1158.
23. Cleland J.G.F., Freemantle N., Ball S.G., et al. The Heart Failure Revascularisation Trial (HEART): rationale, design and methodology. Eur J Heart Fail. 5:2003;295-303.
24. Feuerstein G.Z., Ruffolo R.R.J. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 16:(suppl F):1995;38-42.
25. Chen C., Ma L., Linfert D.R., et al. Myocardial cell death and apoptosis in hibernating myocardium. J Am Coll Cardiol. 30:1997;1407-1412.
26. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., Eichhorn E.J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 25:1995;1154-1161.